FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer
CHICAGO — Patients with FGFR-mutated advanced urothelial cancer that progressed after anti-PD-1/L1 therapy lived significantly longer if they received the selective FGFR inhibitor erdafitinib (Balversa) instead of chemotherapy, a randomized trial showed. Median overall survival (OS) increased from 7.8 months with physician’s choice of chemotherapy to 12.1 months with the targeted agent. Progression-free survival (PFS) […]